Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first‑line treatment for Japanese patients with metastatic colorectal cancer

Uchima,Yasutake; Nishii,Takafumi; Iseki,Yasuhito; Ishii,Mariko; Hiramatsu,Soichiro; Iwauchi,Takehiko; Morimoto,Junya; Kosaka,Kinshi; Tei,Seika; Takeuchi,Kazuhiro

doi:10.3892/mco.2013.205

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first‑line treatment for Japanese patients with metastatic colorectal cancer

Authors:
- Yasutake Uchima
- Takafumi Nishii
- Yasuhito Iseki
- Mariko Ishii
- Soichiro Hiramatsu
- Takehiko Iwauchi
- Junya Morimoto
- Kinshi Kosaka
- Seika Tei
- Kazuhiro Takeuchi
View Affiliations

Affiliations: Department of Surgery, Fuchu Hospital, Izumi, Osaka 5940076, Japan
Published online on: October 22, 2013 https://doi.org/10.3892/mco.2013.205
Pages: 134-138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

XELOX plus bevacizumab is an effective treatment strategy and has a manageable tolerability profile when administered to Japanese patients with metastatic colorectal cancer (mCRC). In this study, we retrospectively reviewed cases in which XELOX plus bevacizumab were administered in order to evaluate its efficacy and safety in clinical practice. In total, 40 patients with mCRC who presented at Fuchu Hospital received XELOX plus bevacizumab as a first‑line treatment between September, 2009 and April, 2012. Eligible patients had histologically confirmed mCRC. XELOX consisted of a 2‑h intravenous infusion of oxaliplatin 130 mg/m2 on day 1 plus oral capecitabine 1,000 mg/m2 twice daily for 2 weeks of a 3‑week cycle. Overall survival (OS) and survival benefit were analyzed when patients continued with XELOX plus bevacizumab beyond disease progression. The median progression‑free survival (PFS) was 290 days [95% confidence interval (CI): 222‑409 days] and the median OS was 816 days (95% CI: 490 days‑not calculated). The response rate (RR; complete plus partial response) was 67.5%, and the disease control rate (RR plus stable disease) was 90%. The most common adverse events observed following administration of XELOX plus bevacizumab were neurosensory toxicity (82.5%), anorexia (50%), hypertension (45%) and a decrease in the platelet count (40%). The most common grade 3/4 adverse events were neurosensory toxicity (15%) and fatigue (15%). In conclusion, XELOX plus bevacizumab may be considered a routine first‑line treatment option for patients with mCRC. Notably, the combination of capecitabine and bevacizumab was safe with an acceptable toxicity profile and induced a significant rate of disease control.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Kotake K, Honjo S, Sugihara K, et al: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum. 46(Suppl 10): S32–S43. 2003.PubMed/NCBI
3.	de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.
4.	Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar
5.	Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 19:2282–2292. 2001.
6.	Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 19:4097–4106. 2001.
7.	Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Ducreux M, Bennouna J, Hebbar M, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastaic colorectal cancer. Int J Cancer. 128:682–690. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 19:1720–1726. 2008. View Article : Google Scholar
11.	Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Doi T, Boku N, Kato K, et al: Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 40:913–920. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 23:3697–3705. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Cassidy J, Clarke S, Diaz-Rubio E, et al: XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 105:58–64. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 26:3523–3539. 2008. View Article : Google Scholar
18.	Hyodo I, Shirao K, Doi T, et al: A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 36:410–417. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Yoshino T, Boku N, Onozawa Y, et al: Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Jpn J Clin Oncol. 37:686–691. 2007. View Article : Google Scholar
20.	Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 26:2118–2123. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Tournigand C, Cervantes A, Figer A, et al: OPTIMOX-1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 24:394–400. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Feliu J, Safont MJ, Salud A, et al: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 102:1468–1473. 2010. View Article : Google Scholar : PubMed/NCBI